KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-02

AUTHORS

Tao Zuo, Serena Wong, Natalia Buza, Pei Hui

ABSTRACT

In contrast to non-invasive extraovarian implants, invasive implants of ovarian serous borderline tumor/atypical proliferative serous tumor are associated with adverse outcome and have been reclassified as low-grade serous carcinoma. Mutations of KRAS and/or BRAF have been reported in up to 50% of serous borderline tumor/atypical proliferative serous tumor. We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome. Forty-two implants of serous borderline tumor from 39 patients were included (invasive implants/low-grade serous carcinoma, n=20; non-invasive implants, n=22). KRAS mutation was found in 12 of 20 invasive implants (60%) and 3 of 22 non-invasive implants (14%). BRAF V600E mutation was found in 1 of 22 non-invasive implants (5%) and none in invasive implants (0%). Invasive implants were more frequently associated with higher stage disease. Nine of 14 patients (64%) with KRAS mutation were found to have stage IIIC disease, while 5 of 24 patients (20%) without the mutation had stage IIIC disease. Patients with invasive implants had higher recurrence rate compared to those with non-invasive implants (60 vs 14 %, P=0.0003, log-rank test) and worse disease-specific survival (P=0.0008, log-rank test). Regardless of the histological subtypes, patients with KRAS mutation positive implants had significantly higher recurrence rate than those without the mutation (71 vs 21%, P=0.0021, log-rank test) and an unfavorable disease-specific survival (P=0.0104, log-rank test). In conclusion, compared to those with non-invasive implants, patients with invasive implants present with higher stage of the disease, higher recurrence rate and worse survival. KRAS mutation, but not BRAF V600E mutation, is significantly associated with invasive implants of serous borderline tumor. Regardless of the histological subtypes of the implants, KRAS mutation is a significant prognostic indicator for high risk of tumor recurrence and worse disease-specific survival. More... »

PAGES

350

References to SciGraph publications

Journal

TITLE

Modern Pathology

ISSUE

2

VOLUME

31

Author Affiliations

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/modpathol.2017.121

DOI

http://dx.doi.org/10.1038/modpathol.2017.121

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092192611

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29027536


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Pathology, Yale University School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zuo", 
        "givenName": "Tao", 
        "id": "sg:person.014522153465.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014522153465.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Pathology, Yale University School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wong", 
        "givenName": "Serena", 
        "id": "sg:person.015556456465.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015556456465.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Pathology, Yale University School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buza", 
        "givenName": "Natalia", 
        "id": "sg:person.01264655440.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264655440.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Pathology, Yale University School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hui", 
        "givenName": "Pei", 
        "id": "sg:person.01057557510.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057557510.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mdw089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000346417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/path.3967", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000606558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/path.4252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000793081"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0000000000000693", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001819136"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0000000000000693", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001819136"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pdm.0b013e318263f092", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002809688"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pdm.0b013e318263f092", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002809688"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw083", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009072963"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw083", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009072963"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/path.4293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015494033"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737159.2015.986102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016465093"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1054/bjoc.2001.1964", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020621721", 
          "https://doi.org/10.1054/bjoc.2001.1964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2014.06.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033021266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19881115)62:10<2212::aid-cncr2820621024>3.0.co;2-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033805649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000478-200104000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047034236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000478-200104000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047034236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-04-2067", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048075701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/95.6.484", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049943179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0000000000000692", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050340710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0000000000000692", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050340710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2559.1984.tb02336.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051887348"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2559.1984.tb02336.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051887348"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074728432", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083347676", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0000000000000824", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084196039"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0000000000000824", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084196039"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02", 
    "datePublishedReg": "2018-02-01", 
    "description": "In contrast to non-invasive extraovarian implants, invasive implants of ovarian serous borderline tumor/atypical proliferative serous tumor are associated with adverse outcome and have been reclassified as low-grade serous carcinoma. Mutations of KRAS and/or BRAF have been reported in up to 50% of serous borderline tumor/atypical proliferative serous tumor. We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome. Forty-two implants of serous borderline tumor from 39 patients were included (invasive implants/low-grade serous carcinoma, n=20; non-invasive implants, n=22). KRAS mutation was found in 12 of 20 invasive implants (60%) and 3 of 22 non-invasive implants (14%). BRAF V600E mutation was found in 1 of 22 non-invasive implants (5%) and none in invasive implants (0%). Invasive implants were more frequently associated with higher stage disease. Nine of 14 patients (64%) with KRAS mutation were found to have stage IIIC disease, while 5 of 24 patients (20%) without the mutation had stage IIIC disease. Patients with invasive implants had higher recurrence rate compared to those with non-invasive implants (60 vs 14 %, P=0.0003, log-rank test) and worse disease-specific survival (P=0.0008, log-rank test). Regardless of the histological subtypes, patients with KRAS mutation positive implants had significantly higher recurrence rate than those without the mutation (71 vs 21%, P=0.0021, log-rank test) and an unfavorable disease-specific survival (P=0.0104, log-rank test). In conclusion, compared to those with non-invasive implants, patients with invasive implants present with higher stage of the disease, higher recurrence rate and worse survival. KRAS mutation, but not BRAF V600E mutation, is significantly associated with invasive implants of serous borderline tumor. Regardless of the histological subtypes of the implants, KRAS mutation is a significant prognostic indicator for high risk of tumor recurrence and worse disease-specific survival.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/modpathol.2017.121", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1098208", 
        "issn": [
          "0893-3952", 
          "1530-0285"
        ], 
        "name": "Modern Pathology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "name": "KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome", 
    "pagination": "350", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3fa49f608da36f7a35334b89d8cb7c16cdae90d79ae0cc711646381b6afd7abb"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29027536"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8806605"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/modpathol.2017.121"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092192611"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/modpathol.2017.121", 
      "https://app.dimensions.ai/details/publication/pub.1092192611"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000573.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/modpathol2017121"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2017.121'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2017.121'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2017.121'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2017.121'


 

This table displays all metadata directly associated to this object as RDF triples.

146 TRIPLES      21 PREDICATES      48 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/modpathol.2017.121 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N4eb664c83f7d4498acdfb16155437a7a
4 schema:citation sg:pub.10.1054/bjoc.2001.1964
5 https://app.dimensions.ai/details/publication/pub.1074728432
6 https://app.dimensions.ai/details/publication/pub.1083347676
7 https://doi.org/10.1002/1097-0142(19881115)62:10<2212::aid-cncr2820621024>3.0.co;2-w
8 https://doi.org/10.1002/path.3967
9 https://doi.org/10.1002/path.4252
10 https://doi.org/10.1002/path.4293
11 https://doi.org/10.1016/j.ygyno.2014.06.002
12 https://doi.org/10.1093/annonc/mdw083
13 https://doi.org/10.1093/annonc/mdw089
14 https://doi.org/10.1093/jnci/95.6.484
15 https://doi.org/10.1097/00000478-200104000-00001
16 https://doi.org/10.1097/pas.0000000000000692
17 https://doi.org/10.1097/pas.0000000000000693
18 https://doi.org/10.1097/pas.0000000000000824
19 https://doi.org/10.1097/pdm.0b013e318263f092
20 https://doi.org/10.1111/j.1365-2559.1984.tb02336.x
21 https://doi.org/10.1158/0008-5472.can-04-2067
22 https://doi.org/10.1586/14737159.2015.986102
23 schema:datePublished 2018-02
24 schema:datePublishedReg 2018-02-01
25 schema:description In contrast to non-invasive extraovarian implants, invasive implants of ovarian serous borderline tumor/atypical proliferative serous tumor are associated with adverse outcome and have been reclassified as low-grade serous carcinoma. Mutations of KRAS and/or BRAF have been reported in up to 50% of serous borderline tumor/atypical proliferative serous tumor. We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome. Forty-two implants of serous borderline tumor from 39 patients were included (invasive implants/low-grade serous carcinoma, n=20; non-invasive implants, n=22). KRAS mutation was found in 12 of 20 invasive implants (60%) and 3 of 22 non-invasive implants (14%). BRAF V600E mutation was found in 1 of 22 non-invasive implants (5%) and none in invasive implants (0%). Invasive implants were more frequently associated with higher stage disease. Nine of 14 patients (64%) with KRAS mutation were found to have stage IIIC disease, while 5 of 24 patients (20%) without the mutation had stage IIIC disease. Patients with invasive implants had higher recurrence rate compared to those with non-invasive implants (60 vs 14 %, P=0.0003, log-rank test) and worse disease-specific survival (P=0.0008, log-rank test). Regardless of the histological subtypes, patients with KRAS mutation positive implants had significantly higher recurrence rate than those without the mutation (71 vs 21%, P=0.0021, log-rank test) and an unfavorable disease-specific survival (P=0.0104, log-rank test). In conclusion, compared to those with non-invasive implants, patients with invasive implants present with higher stage of the disease, higher recurrence rate and worse survival. KRAS mutation, but not BRAF V600E mutation, is significantly associated with invasive implants of serous borderline tumor. Regardless of the histological subtypes of the implants, KRAS mutation is a significant prognostic indicator for high risk of tumor recurrence and worse disease-specific survival.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf Na12fd3e2f57541c9b99bcebe14db815c
30 Nbfb07dc4fff542ec9caba208404c6c5c
31 sg:journal.1098208
32 schema:name KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome
33 schema:pagination 350
34 schema:productId N1e314384f8744ff3ba7dd47b1840ce74
35 N311c7967c6604dc9bb565b7a2e5b06e1
36 N3b7d9d263c0b4818aae1c3f9a6447f49
37 N8dd8b89d608f493cbbd734444a6ddd68
38 N9e1bfb5de5944f4487ee5b16e5bf5454
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092192611
40 https://doi.org/10.1038/modpathol.2017.121
41 schema:sdDatePublished 2019-04-10T22:42
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher N2edc02d9bf014ed8895778e0173a3022
44 schema:url https://www.nature.com/articles/modpathol2017121
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N0ad9ff026f3c46c7800663c0d9a70476 rdf:first sg:person.015556456465.32
49 rdf:rest N647c02abdf72471480e6d1d2383a3a74
50 N1e314384f8744ff3ba7dd47b1840ce74 schema:name readcube_id
51 schema:value 3fa49f608da36f7a35334b89d8cb7c16cdae90d79ae0cc711646381b6afd7abb
52 rdf:type schema:PropertyValue
53 N2edc02d9bf014ed8895778e0173a3022 schema:name Springer Nature - SN SciGraph project
54 rdf:type schema:Organization
55 N311c7967c6604dc9bb565b7a2e5b06e1 schema:name nlm_unique_id
56 schema:value 8806605
57 rdf:type schema:PropertyValue
58 N3b7d9d263c0b4818aae1c3f9a6447f49 schema:name doi
59 schema:value 10.1038/modpathol.2017.121
60 rdf:type schema:PropertyValue
61 N41a25b78269b44828e3a1f0c91b10d41 rdf:first sg:person.01057557510.46
62 rdf:rest rdf:nil
63 N4eb664c83f7d4498acdfb16155437a7a rdf:first sg:person.014522153465.08
64 rdf:rest N0ad9ff026f3c46c7800663c0d9a70476
65 N647c02abdf72471480e6d1d2383a3a74 rdf:first sg:person.01264655440.98
66 rdf:rest N41a25b78269b44828e3a1f0c91b10d41
67 N8dd8b89d608f493cbbd734444a6ddd68 schema:name dimensions_id
68 schema:value pub.1092192611
69 rdf:type schema:PropertyValue
70 N9e1bfb5de5944f4487ee5b16e5bf5454 schema:name pubmed_id
71 schema:value 29027536
72 rdf:type schema:PropertyValue
73 Na12fd3e2f57541c9b99bcebe14db815c schema:issueNumber 2
74 rdf:type schema:PublicationIssue
75 Nbfb07dc4fff542ec9caba208404c6c5c schema:volumeNumber 31
76 rdf:type schema:PublicationVolume
77 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
78 schema:name Medical and Health Sciences
79 rdf:type schema:DefinedTerm
80 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
81 schema:name Oncology and Carcinogenesis
82 rdf:type schema:DefinedTerm
83 sg:journal.1098208 schema:issn 0893-3952
84 1530-0285
85 schema:name Modern Pathology
86 rdf:type schema:Periodical
87 sg:person.01057557510.46 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
88 schema:familyName Hui
89 schema:givenName Pei
90 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057557510.46
91 rdf:type schema:Person
92 sg:person.01264655440.98 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
93 schema:familyName Buza
94 schema:givenName Natalia
95 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264655440.98
96 rdf:type schema:Person
97 sg:person.014522153465.08 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
98 schema:familyName Zuo
99 schema:givenName Tao
100 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014522153465.08
101 rdf:type schema:Person
102 sg:person.015556456465.32 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
103 schema:familyName Wong
104 schema:givenName Serena
105 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015556456465.32
106 rdf:type schema:Person
107 sg:pub.10.1054/bjoc.2001.1964 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020621721
108 https://doi.org/10.1054/bjoc.2001.1964
109 rdf:type schema:CreativeWork
110 https://app.dimensions.ai/details/publication/pub.1074728432 schema:CreativeWork
111 https://app.dimensions.ai/details/publication/pub.1083347676 schema:CreativeWork
112 https://doi.org/10.1002/1097-0142(19881115)62:10<2212::aid-cncr2820621024>3.0.co;2-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1033805649
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1002/path.3967 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000606558
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1002/path.4252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000793081
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1002/path.4293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015494033
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1016/j.ygyno.2014.06.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033021266
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1093/annonc/mdw083 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009072963
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1093/annonc/mdw089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000346417
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1093/jnci/95.6.484 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049943179
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1097/00000478-200104000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047034236
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1097/pas.0000000000000692 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050340710
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1097/pas.0000000000000693 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001819136
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1097/pas.0000000000000824 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084196039
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1097/pdm.0b013e318263f092 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002809688
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1111/j.1365-2559.1984.tb02336.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051887348
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1158/0008-5472.can-04-2067 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048075701
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1586/14737159.2015.986102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016465093
143 rdf:type schema:CreativeWork
144 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
145 schema:name Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
146 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...